Passage Bio Inc expected to post a loss of $4.05 a share - Earnings Preview

Passage Bio

04/08/2025 14:25

Passage Bio Inc PASG.OQ PASG.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Passage Bio Inc is for a loss of $4.05 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Passage Bio Inc is $100.00, about 94.3% above its last closing price of $5.74

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-4.61
-4.60
-5.00
Missed
-8.7
Dec. 31 2025
-4.53
-4.08
-4.00
Beat
2
Sep. 30 2024
-4.23
-4.60
-6.20
Missed
-34.8​
Jun. 30 2024
-6.11
-6.20
-5.20
Beat
16.1
​​Mar. 31 2024
-7.22
-7.15
-6.00
Beat
16.1
Dec. 31 2023
-7.99
-8.04
-6.00
Beat
25.3​
Sep. 30 2023
-9.48
-9.12
-9.80
Missed
-7.4
Jun. 30 2023
-9.43
-9.57
-8.80
Beat
8

This summary was machine generated August 4 at 13:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)